# Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

> **NCT00349466** · PHASE2 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 80 (actual)

## Conditions studied

- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** CF101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00349466
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349466, "Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00349466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*